Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid brewing economic concerns, investors seeking upside opportunities in the equities sector should consider biotech stocks to buy for one simple reason: extraordinary and permanent relevance. No matter what happens to the...
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), today announced that it is accepting proposals for the fourth annual Access to Excellent Care for Sickle Cell Patients...
Commercial-stage biotech Global Blood Therapeutics (NASDAQ:GBT) announced on Monday that the FDA granted both orphan drug and rare pediatric disease designations for inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease (SCD). A human monoclonal antibody, Inclacumab, is c...
Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive crises (VOCs) and readmissions due to VOCs in patients with sickle cell disease GBT601 is a next generation sickle hemoglobin (HbS) polymerization inhibitor expected to a...
Gainers: Repare Therapeutics (RPTX) +20%. Credo Technology Group Holding (CRDO) +8%. Elevation Oncology (ELEV) +8%. MongoDB (MDB) +6%. Global Blood Therapeutics (GBT) +5%. Losers: Charge Enterprises (CRGE) -5%. NerdWallet (NRDS) -5%. Protagonist Therapeutics (PTGX) -5%. ...
Conference call and webcast will include data presented at EHA 2022 and business and R&D updates Company to also participate in the William Blair and Goldman Sachs investor conferences SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Global Blood Therap...
Global Blood Therapeutics (NASDAQ:GBT) may be a potential acquisition candidate in the biotech space following Pfizer (PFE)'s deal to acquire Biohaven Pharmaceutical for about $11.6 billion, according to a Wedbush analyst. "In light of Pfizer’s $12 billion acquisition of Biohaven Pharm...
New real-world evidence data on Oxbryta ® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASD...
After market hours on Wednesday, Global Blood Therapeutics (NASDAQ: GBT) released a first-quarter earnings report that investors didn't digest well. As a result, the following day, the stock fell by 8% -- a steep rate, even on a very bearish day when the S&P 500 index declin...
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q1 2022 Earnings Call May 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript ...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...